SCHEMBL6524338

SCHEMBL6524338

CC1=C(C(=O)O)C(c2cccc(Cl)c2)N(CCCN(CC(=O)c2ccc(N3C(=O)c4ccccc4C3=O)cc2)c2ccccc2)C(=O)N1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.38
CCR1 P32246 1/20 0.36
FFAR1 O14842 1/20 0.36
TP53 P04637 2/20 0.35
HTT P42858 2/20 0.35
NPSR1 Q6W5P4 2/20 0.35
ALOX15 P16050 1/20 0.35
TSHR P16473 1/20 0.35
MAPK1 P28482 1/20 0.35
CACNA1B Q00975 5/20 0.34
ADCY2 Q08462 1/20 0.34
USP2 O75604 1/20 0.34
LMNA P02545 1/20 0.34
CA12 O43570 1/20 0.34
CA1 P00915 1/20 0.34
CA2 P00918 1/20 0.34
CA9 Q16790 1/20 0.34
SCN2A Q99250 1/20 0.34
ADRA1D P25100 1/20 0.34
ADRA1A P35348 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5568267 0.88 HTT (0.39) MAPTCCR1FFAR1TP53HTT
SCHEMBL5568264 0.84 ADRA1D (0.39) MAPTCCR1FFAR1TP53HTT
SCHEMBL6524348 0.83 ADCY2 (0.36) MAPTCCR1FFAR1TP53HTT
SCHEMBL5562887 0.77 HTT (0.43) MAPTHTTCACNA1BADRA1DADRA1A
SCHEMBL5563145 0.75 CACNA1B (0.43) MAPTTP53HTTTSHRCACNA1B
SCHEMBL5568028 0.74 HTT (0.40) HTTCACNA1BADRA1DADRA1AADRA1B
SCHEMBL5567175 0.74 HTT (0.40) MAPTCCR1HTTCACNA1BADRA1D
SCHEMBL5564795 0.74 HTT (0.41) HTTCACNA1BUSP2ADRA1DADRA1A
SCHEMBL5567824 0.73 HTT (0.39) MAPTHTTCACNA1BADRA1DADRA1A
SCHEMBL5562891 0.73 ADRA1D (0.42) MAPTFFAR1TP53HTTNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050043339-A1 Dihydropyrimidone inhibitors of calcium channel function BRISTOL-MYERS SQUIBB COMPANY 2005-02-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050043339-A1 Dihydropyrimidone inhibitors of calcium channel function CACNA1E, CACNA1C, CACNA1S MAPT 1236/4885CCR1 3435/4885FFAR1 983/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.